

A study on the use of TK1 to monitor prostate cancer has been accepted for poster presentation at the AACR annual meeting 2020

A study by Professor Teemu Murtola of Tampere University Hospital, Finland, on the use of Thymidine Kinase 1 as a marker for the risk of prostate cancer progression following diagnosis has now been accepted for poster presentation on the American Association of Cancer Research 2020 (AACR 2020) held in San Diego, California, USA.

The poster is entitled "Serum Thymidine Kinase 1 levels predict prostate cancer-specific survival" and is based on a study by Teemu Murtola of Tampere University Hospital. In the study the samples from two groups of men were used; one with localized prostate cancer and another with metastatic disease at diagnosis. Serum Thymidine kinase 1 (TK1) protein levels at the time of diagnosis were measured with AroCell TK210 ELISA and compared with the extent and speed of disease progression over a period of 10 years.

The abstract of the study will be published online on the AACR website on Tuesday, March 24, 2020, and the poster will be presented on Monday, April 27.

Contacts

Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20
E-mail: michael.brobjer@arocell.com

About Thymidine Kinase 1

Thymidine Kinase 1 (TK1) is a key enzyme in DNA precursor synthesis. It is upregulated during the late G1 phase and early S phase of the cell cycle and its presence in cells is an indicator of active cell proliferation. Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example therapeutic agents.

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com

Attachments

[A study on the use of TK1 to monitor prostate cancer has been accepted for poster presentation at the AACR annual meeting 2020](#)